Yves-Jean Bignon

Yves-Jean Bignon

Auto-generated profile, based on publicly available information

Yves-Jean Bignon

Centre Jean Perrin

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in European Journal of Cancer
Verified
Journal Article
Open access
PPP. Pujol
P. Pujol
Massimo BarberisMassimo Barberis
Massimo Barberis
PBPhilip Beer
Philip Beer
EFEitan Friedman
Eitan Friedman
JPJosep M. Piulats
Josep M. Piulats
JMJose E. Alés Martínez
Jose E. Alés Martínez
BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer. Because issues of BRCA testing in clinical practice now overlap with both preventive and therapeutic management, updated and comprehensive practice guidelines for BRCA genotyping are needed. The integrative recommendations for BRCA testing presented here aim to (1) identify individuals who may benefit from genetic counselling and risk-reducing strategies; (2) update germline and tumour-testing indications for PARPi-approved therapies; (3) provide testing recommendations for personalised management of early and metastatic breast cancer; and (4) address the issues of rapid process and tumour analysis. An international group of experts, including geneticists, medical and surgical oncologists, pathologists, ethicists and patient representatives, was commissioned by the French Society of Predictive and Personalised Medicine (SFMPP). The group followed a methodology based on specific formal guidelines development, including (1) evaluating the likelihood of BRCAm from a combined systematic review of the literature, risk assessment models and expert quotations, and (2) therapeutic values of BRCAm status for PARPi therapy in BRCA-related cancer and for management of early and advanced breast cancer. These international guidelines may help clinicians comprehensively update and standardise BRCA testing practices.

15 September 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
AGAbderrahim El Guerrab
Abderrahim El Guerrab
MBMahchid BAMDAD
Mahchid BAMDAD
FKFabrice Kwiatkowski
Fabrice Kwiatkowski
YBYves-Jean Bignon
Yves-Jean Bignon
FPFrédérique Penault-Llorca
Frédérique Penault-Llorca
CACorinne Aubel
Corinne Aubel
Oncotarget | https://doi.org/10.18632/oncotarget.12037 Abderrahim El Guerrab, Mahchid Bamdad, Fabrice Kwiatkowski, Yves-Jean Bignon, Frédérique Penault-Llorca, Corinne Aubel Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer

10 July 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMaud Privat
Maud Privat
NRNina Radosevic-Robin
Nina Radosevic-Robin
CACorinne Aubel
Corinne Aubel
ACAnne Cayre
Anne Cayre
FPFrédérique Penault-Llorca
Frédérique Penault-Llorca
DMDaniel Morvan
Daniel Morvan
The hypermetabolic nature of cancer cells and their increased reliance on “aerobic glycolysis”, as originally described by Otto Warburg and colleagues, are considered metabolic hallmarks of cancer cells. BRCA1 is a major tumor suppressor in breast cancer and it was implicated in numerous pathways resulting in anticarcinogenic functions. The objective of our study was to address specific contributions of BRCA1 to the metabolic features of cancer cells, including the so-called “Warburg effect”. To get a comprehensive approach of the role of BRCA1 in tumor cell metabolism, we performed a global transcriptional and metabolite profiling in a BRCA1-mutated breast cancer cell line transfected or not by wild-type BRCA1. This study revealed that BRCA1 induced numerous modifications of metabolism, including strong inhibition of glycolysis while TCA cycle and oxidative phosphorylation tended to be activated. Regulation of AKT by BRCA1 in both our cell model and BRCA1-mutated breast tumors was suggested to participate in the effect of BRCA1 on glycolysis. We could also show that BRCA1 induced a decrease of ketone bodies and free fatty acids, maybe consumed to supply Acetyl-CoA for TCA cycle. Finally increased activity of antioxidation pathways was observed in BRCA1-transfected cells, that could be a consequence of ROS production by activated oxidative phosphorylation. Our study suggests a new function for BRCA1 in cell metabolic regulation, globally resulting in reversion of the Warburg effect. This could represent a new mechanism by which BRCA1 may exert tumor suppressor function.

7 December 2015 in Epigenomics
Verified
Journal Article
Closed access
GJGaëlle Judes
Gaëlle Judes
KRKhaldoun RIFAI
Khaldoun RIFAI
MNMarjolaine Ngollo
Marjolaine Ngollo
MDMarine Daures
Marine Daures
YBYves-Jean Bignon
Yves-Jean Bignon
DBDominique Bernard-Gallon
Dominique Bernard-Gallon
Acetylation is a major modification that is required for gene regulation, genome maintenance and metabolism. A dysfunctional acetylation plays an important role in several diseases, including cancer. A group of enzymes-lysine acetyltransferases are responsible for this modification and act in regulation of transcription as cofactors and by acetylation of histones and other proteins. Tip60, a member of MYST family, is expressed ubiquitously and is the acetyltransferase catalytic subunit of human NuA4 complex. This HAT has a well-characterized involvement in many processes, such as cellular signaling, DNA damage repair, transcriptional and cellular cycle. Aberrant lysine acetyltransferase functions promote or suppress tumorigenesis in different cancers such as colon, breast and prostate tumors. Therefore, Tip60 might be a potential and important therapeutic target in the cancer treatment; new histone acetyl transferase inhibitors were identified and are more selective inhibitors of Tip60.

24 November 2011 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
ADAlexis Desrichard
Alexis Desrichard
YBYannick Bidet
Yannick Bidet
NUNancy Uhrhammer
Nancy Uhrhammer
YBYves-Jean Bignon
Yves-Jean Bignon
Background: Mutations in the BRCA1 and BRCA2 genes are responsible for only a part of hereditary breast cancer (HBC). The origins of "non-BRCA" HBC in families may be attributed in part to rare mutations in genes conferring moderate risk, such as CHEK2, which encodes for an upstream regulator of BRCA1. Previous studies have demonstrated an association between CHEK2 founder mutations and non-BRCA HBC. However, very few data on the entire coding sequence of this gene are available. Methods: We investigated the contribution of CHEK2 mutations to non-BRCA HBC by direct sequencing of its whole coding sequence in 507 non-BRCA HBC cases and 513 controls. Results: We observed 16 mutations in cases and 4 in controls, including 9 missense variants of uncertain consequence. Using both in silico tools and an in vitro kinase activity test, the majority of the variants were found likely to be deleterious for protein function. One variant present in both cases and controls was proposed to be neutral. Removing this variant from the pool of potentially deleterious variants gave a mutation frequency of 1.48% for cases and 0.29% for controls (P = 0.0040). The odds ratio of breast cancer in the presence of a deleterious CHEK2 mutation was 5.18. Conclusions: Our work indicates that a variety of deleterious CHEK2 alleles make an appreciable contribution to breast cancer susceptibility, and their identification could help in the clinical management of patients carrying a CHEK2 mutation.

1 January 2008 in International Journal of Medical Sciences
Verified
Journal Article
Open access
NUNancy Uhrhammer
Nancy Uhrhammer
AAAmina Abdelouahab
Amina Abdelouahab
LLLaurence Lafarge
Laurence Lafarge
VFViviane Feillel
Viviane Feillel
ADAhmed Ben Dib
Ahmed Ben Dib
YBYves-Jean Bignon
Yves-Jean Bignon
Breast cancer rates and median age of onset differ between Western Europe and North Africa. In Western populations, 5 to 10 % of breast cancer cases can be attributed to major genetic factors such as BRCA1 and BRCA2, while this attribution is not yet well defined among Africans. To help determine the contribution of BRCA1 mutations to breast cancer in a North African population, we analysed genomic DNA from breast cancer cases ascertained in Algiers.